PRVA Quote, Financials, Valuation and Earnings

DarioHealth Corp. has a net margin of 1.69% compared to Privia Health Group, Inc.'s net margin of -41.48%. Privia Health Group, Inc.'s return on equity of 3.45% beat DarioHealth Corp.'s return on equity of -41.55%.

Privia Health Group, Inc. has a consensus price target of $31.11, signalling upside risk potential of 30.48%. On the other hand DarioHealth Corp. has an analysts' consensus of $18.25 which suggests that it could grow by 54.14%. Given that DarioHealth Corp. has higher upside potential than Privia Health Group, Inc., analysts believe DarioHealth Corp. is more attractive than Privia Health Group, Inc..

Privia Health Group, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DarioHealth Corp. has a beta of 1.077, suggesting its more volatile than the S&P 500 by 7.716%.

Privia Health Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DarioHealth Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Privia Health Group, Inc. pays -- of its earnings as a dividend. DarioHealth Corp. pays out -- of its earnings as a dividend.

Privia Health Group, Inc. quarterly revenues are $580.4M, which are larger than DarioHealth Corp. quarterly revenues of $5M. Privia Health Group, Inc.'s net income of $9.8M is higher than DarioHealth Corp.'s net income of -$2.1M. Notably, Privia Health Group, Inc.'s price-to-earnings ratio is 167.89x while DarioHealth Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Privia Health Group, Inc. is 1.49x versus 6.57x for DarioHealth Corp.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of 1.69% compared to Privia Health Group, Inc.'s net margin of 11.54%. Privia Health Group, Inc.'s return on equity of 3.45% beat National Research Corp.'s return on equity of 61.55%.

Privia Health Group, Inc. has a consensus price target of $31.11, signalling upside risk potential of 30.48%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Privia Health Group, Inc. has higher upside potential than National Research Corp., analysts believe Privia Health Group, Inc. is more attractive than National Research Corp..

Privia Health Group, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

Privia Health Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 3.03% to investors and pays a quarterly dividend of $0.12 per share. Privia Health Group, Inc. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Privia Health Group, Inc. quarterly revenues are $580.4M, which are larger than National Research Corp. quarterly revenues of $34.6M. Privia Health Group, Inc.'s net income of $9.8M is higher than National Research Corp.'s net income of $4M. Notably, Privia Health Group, Inc.'s price-to-earnings ratio is 167.89x while National Research Corp.'s PE ratio is 22.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Privia Health Group, Inc. is 1.49x versus 2.60x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology, Inc. has a net margin of 1.69% compared to Privia Health Group, Inc.'s net margin of -2156852.78%. Privia Health Group, Inc.'s return on equity of 3.45% beat Predictive Oncology, Inc.'s return on equity of -1065.31%.

Privia Health Group, Inc. has a consensus price target of $31.11, signalling upside risk potential of 30.48%. On the other hand Predictive Oncology, Inc. has an analysts' consensus of -- which suggests that it could grow by 956.34%. Given that Predictive Oncology, Inc. has higher upside potential than Privia Health Group, Inc., analysts believe Predictive Oncology, Inc. is more attractive than Privia Health Group, Inc..

Privia Health Group, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Predictive Oncology, Inc. has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.357%.

Privia Health Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Privia Health Group, Inc. pays -- of its earnings as a dividend. Predictive Oncology, Inc. pays out -- of its earnings as a dividend.

Privia Health Group, Inc. quarterly revenues are $580.4M, which are larger than Predictive Oncology, Inc. quarterly revenues of $3.6K. Privia Health Group, Inc.'s net income of $9.8M is higher than Predictive Oncology, Inc.'s net income of -$77.6M. Notably, Privia Health Group, Inc.'s price-to-earnings ratio is 167.89x while Predictive Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Privia Health Group, Inc. is 1.49x versus 13.06x for Predictive Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of 1.69% compared to Privia Health Group, Inc.'s net margin of 9.46%. Privia Health Group, Inc.'s return on equity of 3.45% beat Spok Holdings, Inc.'s return on equity of 10.88%.

Privia Health Group, Inc. has a consensus price target of $31.11, signalling upside risk potential of 30.48%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 61.29%. Given that Spok Holdings, Inc. has higher upside potential than Privia Health Group, Inc., analysts believe Spok Holdings, Inc. is more attractive than Privia Health Group, Inc..

Privia Health Group, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

Privia Health Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.6% to investors and pays a quarterly dividend of $0.31 per share. Privia Health Group, Inc. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

Privia Health Group, Inc. quarterly revenues are $580.4M, which are larger than Spok Holdings, Inc. quarterly revenues of $33.9M. Privia Health Group, Inc.'s net income of $9.8M is higher than Spok Holdings, Inc.'s net income of $3.2M. Notably, Privia Health Group, Inc.'s price-to-earnings ratio is 167.89x while Spok Holdings, Inc.'s PE ratio is 16.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Privia Health Group, Inc. is 1.49x versus 1.93x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.